HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mankoff, D. A. Articles by Krohn, K. A. Search for Related Content PubMed PubMed Citation Articles by Mankoff, D. A. Articles by Krohn, K. A.

[¹⁸F]Fluoroestradiol Radiation Dosimetry in Human PET Studies

Departments of Radiology and Medical Oncology, University of Washington School of Medicine, Seattle, Washington

[¹⁸F]16-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies. Methods: Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after intravenous injection of FES. Radiation absorbed doses were calculated using the procedures of the MIRD committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. Effective dose equivalent was calculated using International Commission on Radiological Protection Publication 60 weights for the standard woman. Results: The effective dose equivalent was 0.022 mSv/MBq (80 mrem/mCi). The organ that received the highest dose was the liver (0.13 mGy/MBq [470 mrad/mCi]), followed by the gallbladder (0.10 mGy/MBq [380 mrad/mCi]) and the urinary bladder (0.05 mGy/MBq [190 mrad/mCi]). Conclusion: The organ doses are comparable to those associated with other commonly performed nuclear medicine tests. FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits.

Key Words: PET • estrogen receptor • fluoroestradiol • dosimetry

This article has been cited by other articles:

				M. D. Szeto, G. Chakraborty, J. Hadley, R. Rockne, M. Muzi, E. C. Alvord Jr., K. A. Krohn, A. M. Spence, and K. R. Swanson Quantitative Metrics of Net Proliferation and Invasion Link Biological Aggressiveness Assessed by MRI with Hypoxia Assessed by FMISO-PET in Newly Diagnosed Glioblastomas Cancer Res., May 15, 2009; 69(10): 4502 - 4509. [Abstract] [Full Text] [PDF]

				J.-M. Beauregard, E. Croteau, N. Ahmed, J. E. van Lier, and F. Benard Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11{beta}-Methoxy-16{alpha}-18F-Fluoroestradiol Using Serial Whole-Body PET/CT J. Nucl. Med., January 1, 2009; 50(1): 100 - 107. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				K. Van Laere, M. Koole, S. M. Sanabria Bohorquez, K. Goffin, I. Guenther, M. J. Belanger, J. Cote, P. Rothenberg, I. De Lepeleire, I. D. Grachev, et al. Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand 18F-MK-9470 in Healthy Subjects J. Nucl. Med., March 1, 2008; 49(3): 439 - 445. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, et al. Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2793 - 2799. [Abstract] [Full Text] [PDF]

				L. M. Cher, C. Murone, N. Lawrentschuk, S. Ramdave, A. Papenfuss, A. Hannah, G. J. O'Keefe, J. I. Sachinidis, S. U. Berlangieri, G. Fabinyi, et al. Correlation of Hypoxic Cell Fraction and Angiogenesis with Glucose Metabolic Rate in Gliomas Using 18F-Fluoromisonidazole, 18F-FDG PET, and Immunohistochemical Studies J. Nucl. Med., March 1, 2006; 47(3): 410 - 418. [Abstract] [Full Text] [PDF]

				H. Vesselle, J. Grierson, L. M. Peterson, M. Muzi, D. A. Mankoff, and K. A. Krohn 18F-Fluorothymidine Radiation Dosimetry in Human PET Imaging Studies J. Nucl. Med., September 1, 2003; 44(9): 1482 - 1488. [Abstract] [Full Text] [PDF]